CVE-2012-0582 in Siebel Clinical
Summary
by MITRE
Unspecified vulnerability in the Siebel Clinical component in Oracle Industry Applications 7.7, 7.8, 8.0.0.x, 8.1.1.x, and 8.2.2.x allows remote authenticated users to affect integrity via unknown vectors related to Web UI.
Be aware that VulDB is the high quality source for vulnerability data.
Analysis
by VulDB Data Team • 03/23/2021
The vulnerability identified as CVE-2012-0582 resides within the Siebel Clinical component of Oracle Industry Applications, affecting versions 7.7, 7.8, 8.0.0.x, 8.1.1.x, and 8.2.2.x. This represents a critical security flaw that undermines the integrity of the system through unspecified attack vectors operating within the Web UI framework. The affected component is part of Oracle's comprehensive suite of industry-specific applications designed for healthcare and clinical research environments, where data integrity is paramount for regulatory compliance and patient safety. The vulnerability's classification as remote authenticated indicates that attackers must possess valid credentials to exploit the flaw, yet the impact on system integrity remains severe enough to warrant immediate attention. This vulnerability falls under the broader category of integrity violations as defined by the Common Weakness Enumeration framework, specifically relating to weaknesses in data integrity mechanisms.
The technical nature of this vulnerability manifests through unknown vectors within the Web UI layer of the Siebel Clinical component, suggesting potential issues with input validation, session management, or data processing within the user interface. The unspecified nature of the attack vectors implies that the exact technical mechanism remains undisclosed, but the impact affects data integrity and potentially allows unauthorized modification of clinical data or system configurations. The Web UI attack surface presents multiple potential entry points for exploitation, including form submissions, parameter manipulation, or session hijacking techniques that could compromise the integrity of clinical trial data, patient records, or regulatory compliance information. This vulnerability's presence in multiple version streams indicates a fundamental architectural flaw rather than a simple patchable issue, requiring comprehensive remediation across the affected application landscape.
The operational impact of this vulnerability extends significantly beyond simple data corruption, as clinical research and healthcare data integrity directly affects patient safety, regulatory compliance, and business continuity. Organizations utilizing Siebel Clinical systems face potential exposure to data manipulation that could alter clinical trial results, compromise patient records, or disrupt regulatory reporting processes. The remote authenticated nature of the attack vector means that insider threats or compromised legitimate user accounts could exploit this vulnerability, creating a particularly dangerous scenario where authorized users with appropriate privileges could undermine system integrity. The potential for cascading effects within clinical research databases, where data integrity is crucial for FDA and other regulatory agency compliance, makes this vulnerability particularly severe in healthcare environments. This situation aligns with attack patterns documented in the MITRE ATT&CK framework under the Data Manipulation tactic, where adversaries seek to alter data to achieve their objectives without necessarily gaining full system compromise.
Mitigation strategies for CVE-2012-0582 require immediate implementation of Oracle security patches and updates across all affected versions of the Siebel Clinical component. Organizations should conduct comprehensive vulnerability assessments to identify systems running the vulnerable versions and implement network segmentation to limit access to the affected Web UI components. Security monitoring should be enhanced to detect anomalous user behavior patterns that might indicate exploitation attempts, particularly focusing on data modification activities within clinical databases. Access controls must be strengthened through multi-factor authentication implementation and regular privilege reviews to minimize the impact of compromised legitimate accounts. Additionally, organizations should consider implementing web application firewalls and input validation controls specifically targeting the Web UI attack surface. The remediation process should include thorough testing of patches in staging environments before production deployment to ensure system stability while addressing the integrity vulnerability. Regular security audits and penetration testing should be conducted to verify the effectiveness of implemented controls and identify potential additional attack vectors within the Siebel Clinical environment.